Colgate-Palmolive (CL) is slated to report its 4Q16 results on January 27. YTD (year-to-date), the stock price of the $59.6 billion consumer products company had risen 2.5% on January 17, 2017. The stock’s weekly and monthly price movements were 1.0% and 1.8%, respectively. Colgate-Palmolive is trading 1.6% above its 20-day moving average, 0.70% above its 50-day moving average, and 4.9% below its 200-day moving average. The company’s stock price fell -1.8% in 2016.
Comparison with peers
Colgate-Palmolive has outperformed Procter & Gamble (PG), The Clorox Company (CLX), Kimberly-Clark (KMB), and the S&P 500 on a YTD basis. YTD, Procter & Gamble’s, Clorox’s, and Kimberly-Clark’s stock had returned 1.3%, 1.1%, and 1.7%, respectively, as of January 17.
As of January 17, the S&P 500 and the Consumer Staples Select Sector SPDR ETF (XLP) had grown 1.3% and 1.0%, respectively. Colgate-Palmolive constitutes 3.3% of XLP.
In 3Q16, Colgate-Palmolive exceeded analysts’ earnings estimate but missed their sales estimate. Foreign exchange fluctuations and the deconsolidation of the company’s Venezuelan business adversely impacted its top line in 3Q16.
With Colgate-Palmolive’s 4Q16 results around the corner, we’ll discuss analysts’ expectations for its 4Q16 sales, segments, and earnings. This series will also discuss the company’s strategies and analysts’ recommendations for Colgate-Palmolive’s stock. In the next part of this series, we’ll start with a discussion on sales expectations for the company.